Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals Digital

METiS and WestVac Biopharma Forge AI Partnership to Develop Personalized mRNA Cancer Vaccines

Fineline Cube Aug 21, 2026
Company Deals

Simcere Secures Greater China Rights to Reyoung Bio’s Long‑Acting RSV Antibody RB0026 Under Priority Review

Fineline Cube Aug 20, 2026
Company Deals

VectorBuilder and Lir Therapeutics Forge AI Collaboration to Optimize AAV Capsids for Clinical Translation

Fineline Cube Aug 20, 2026
Company Deals

LEO Pharma to Acquire Global Rights to Dersimelagon From Tanabe – Late‑Stage Oral Therapy for Rare Protoporphyrias Nears FDA Decision

Fineline Cube Aug 20, 2026
Company Deals

Bio-Thera Solutions Expands Partnership with Avalon Pharma: Exclusive MENA Licensing Deal for Dupixent Biosimilar BAT2406 – Second Collaboration After BAT3306

Fineline Cube Aug 19, 2026
Policy / Regulatory

China NHC Mandates Priority Use of Essential Medicines as 2026 National List Takes Effect

Fineline Cube Aug 21, 2026
Company Drug

Leads Biolabs Files NDA for Opamtistomig in EP-NEC — World’s First 4-1BB Bispecific Nears Potential First Approval

Fineline Cube Aug 24, 2026
Company Drug

Yipinhong Wins NMPA Clinical Trial Approval for Category 1 URAT1 Inhibitor APH03867 in Gout and Hyperuricemia

Fineline Cube Aug 24, 2026
Company Deals

BeiGene Ltd Acquires Global Rights to CSPC’s MAT2A Inhibitor SYH2039

Fineline Cube Dec 13, 2024

BeiGene Ltd (NASDAQ: BGNE, HKG: 6160, SHA: 688235) has entered into a significant licensing agreement...

Company Drug

Gan & Lee Pharmaceuticals Gets FDA Approval for GZR18 Obesity/Overweight Phase II Study

Fineline Cube Dec 13, 2024

China-based Gan & Lee Pharmaceuticals (SHA: 603087) has announced that it has received approval from...

Company Drug

HutchMed’s Orpathys Receives Breakthrough Therapy Designation in China for Advanced Lung Cancer

Fineline Cube Dec 13, 2024

HutchMed (China) Ltd (HKG: 0013, NASDAQ: HCM) has announced that its MET inhibitor, Orpathys (savolitinib),...

Company Drug

HutchMed to Receive Milestone Payment as Takeda’s Fruzaqla Gets Reimbursement Nod in Spain

Fineline Cube Dec 13, 2024

China-based HutchMed (China) Ltd (HKG: 0013, NASDAQ: HCM) is poised to receive another milestone payment...

Policy / Regulatory

National VBP Program Round 10: 195 Manufacturers Secure Winning Bids for 62 Drugs

Fineline Cube Dec 13, 2024

The preliminary outcomes of the 10th round of China’s national volume-based procurement (VBP) program were...

Company Medical Device

Grand Pharmaceutical Group Receives NMPA Approval for NOVASYNC HYBRID SYSTM

Fineline Cube Dec 13, 2024

China-based Grand Pharmaceutical Group Co., Ltd. (HKG: 0512) has announced that it has received marketing...

Company Drug

HuidaGene Therapeutics Launches MUSCLE Study for CRISPR Therapy in Duchenne Muscular Dystrophy

Fineline Cube Dec 13, 2024

Shanghai-based genome medicines specialist HuidaGene Therapeutics has announced the initiation of the MUSCLE study for...

Company Deals

Sunshine Lake Pharma Files for HKEX IPO, Expanding Global Pharmaceutical Reach

Fineline Cube Dec 13, 2024

China-based Sunshine Lake Pharma Co., Ltd has submitted an initial public offering (IPO) filing to...

Company Drug

Transcenta’s LIV-1 ADCs Show Promising Results in Pre-Clinical Breast Cancer Study

Fineline Cube Dec 13, 2024

China-based biotech company Transcenta Holdings Ltd (HKG: 6628) announced updated results from a pre-clinical study...

Company Deals

Mabwell Bioscience Secures Licensing Deal with TABUK Pharmaceutical for MENA Region

Fineline Cube Dec 12, 2024

China-based Mabwell (Shanghai) Bioscience Co., Ltd. (SHA: 688062) has inked a licensing deal with TABUK...

Company Drug

ImmunoTech Biopharm’s CAR-T-19 Earns Breakthrough Therapy Designation for B-ALL Treatment

Fineline Cube Dec 12, 2024

China-based chimeric antigen receptor T-cell (CAR-T) specialist Immunotech Biopharm Ltd (HKG: 6978) has announced receiving...

Company Deals

Grand Pharmaceutical Group Secures Licensing Agreement for CORXEL’s Nasal Sprays in Greater China

Fineline Cube Dec 12, 2024

China-based Grand Pharmaceutical Group Co., Ltd. (HKG: 0512) has announced a significant licensing agreement with...

Company Deals

EOSVISION Ltd Secures Series A Funding to Advance Ophthalmic Implant Development

Fineline Cube Dec 12, 2024

Suzhou-based EOSVISION Ltd has reportedly raised close to RMB 100 million (USD 13.78 million) in...

Company Drug

Jiangsu Hengrui Pharmaceuticals Receives NMPA Clearance for HRS-4729 Peptide Drug

Fineline Cube Dec 12, 2024

Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) has announced the receipt of clinical clearance from...

Company

VIVA Biotech Expands Global Footprint with New Boston Branch

Fineline Cube Dec 12, 2024

China-based Contract Research Organization (CRO) VIVA Biotech (HKG: 1873) has announced the inauguration of its...

Company Deals

Siemens Healthineers AG Acquires Advanced Accelerator Applications to Boost PETNET Solutions

Fineline Cube Dec 12, 2024

Germany-based Siemens Healthineers AG (ETR: SHL) has announced the completion of its acquisition of Advanced...

Company Deals

Angitia Biopharmaceuticals Secures USD 120 Million in Series C Financing for Musculoskeletal Treatments

Fineline Cube Dec 12, 2024

Angitia Biopharmaceuticals, a provider of solutions for musculoskeletal diseases operating out of Guangzhou, China, and...

Company Deals

MDHC Life Technologies Secures Series C++ Funding to Boost Consumer Healthcare and Life Sciences

Fineline Cube Dec 12, 2024

China-based Contract Development Manufacturing Organization (CDMO) MDHC Life Technologies (Kunshan) Co.,Ltd has reportedly raised hundreds...

Company

Bayer AG’s Shanghai Co.Lab to Host Epigenic Therapeutics and Peers for CGT Innovation

Fineline Cube Dec 12, 2024

Germany-based Bayer AG (ETR: BAYN) has announced that Chinese companies Epigenic Therapeutics, Shanghai Immunocan Biotech...

Company Drug

AstraZeneca’s Lynparza Shows Sustained Improvements in OlympiA Phase III Study

Fineline Cube Dec 12, 2024

UK pharmaceutical major AstraZeneca (AZ; NASDAQ: AZN) has updated data from the Phase III OlympiA...

Posts pagination

1 … 292 293 294 … 711

Recent updates

  • Leads Biolabs Files NDA for Opamtistomig in EP-NEC — World’s First 4-1BB Bispecific Nears Potential First Approval
  • Yipinhong Wins NMPA Clinical Trial Approval for Category 1 URAT1 Inhibitor APH03867 in Gout and Hyperuricemia
  • ImmuneOnco’s IMM0306 Wins FDA IND Clearance for SLE — World’s First CD47/CD20 Bispecific in Clinic Enters U.S.
  • North China Pharma Wins NMPA Clinical Trial Approval for World-First Hexavalent Norovirus Vaccine Candidate
  • Simcere H1 Earnings Surge as Neuroscience Revenue Jumps 60.9% and Profit Rises 37.9%
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Leads Biolabs Files NDA for Opamtistomig in EP-NEC — World’s First 4-1BB Bispecific Nears Potential First Approval

Company Drug

Yipinhong Wins NMPA Clinical Trial Approval for Category 1 URAT1 Inhibitor APH03867 in Gout and Hyperuricemia

Company Drug

ImmuneOnco’s IMM0306 Wins FDA IND Clearance for SLE — World’s First CD47/CD20 Bispecific in Clinic Enters U.S.

Company Drug

North China Pharma Wins NMPA Clinical Trial Approval for World-First Hexavalent Norovirus Vaccine Candidate

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.